Last reviewed · How we verify

Bioprojet — Portfolio Competitive Intelligence Brief

Bioprojet pipeline: 0 marketed, 0 filed, 3 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 5 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
BF2.649 BF2.649 phase 3 Histamine H3 receptor antagonist H3 receptor Neurology
BF2.649 (pitolisant) BF2.649 (pitolisant) phase 3 Histamine H3 receptor antagonist H3 receptor Neurology
BF2.649 add on Modafinil BF2.649 add on Modafinil phase 3 Histamine H3 receptor antagonist Histamine H3 receptor (H3R) Neurology / Sleep Medicine

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 2 shared drug classes
  2. Boryung Pharmaceutical Co., Ltd · 2 shared drug classes
  3. GlaxoSmithKline · 2 shared drug classes
  4. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  5. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  6. Beijing Tide Pharmaceutical Co., Ltd · 1 shared drug class
  7. Addpharma Inc. · 1 shared drug class
  8. Ace Cells Lab Limited · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Bioprojet:

Cite this brief

Drug Landscape (2026). Bioprojet — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioprojet. Accessed 2026-05-14.

Related